Dow Jones

41,332.73

-1.38%

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

Inicio
Invertir
Acciones
Estados Unidos
NASDAQ
Theravance Biopharma Inc (TBPH)
Theravance Biopharma Inc (TBPH) Noticias

TBPH

Theravance Biopharma (TBPH)

Theravance Biopharma Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:TBPH

1 2 3 4 5 6 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
07/03/2025	05:15	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:TBPH	Theravance Biopharma Inc
04/03/2025	17:11	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:TBPH	Theravance Biopharma Inc
26/02/2025	15:13	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:TBPH	Theravance Biopharma Inc
26/02/2025	15:05	PR Newswire (US)	Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results	NASDAQ:TBPH	Theravance Biopharma Inc
20/02/2025	05:00	PR Newswire (US)	Theravance Biopharma to Participate in an Upcoming Investor Conference	NASDAQ:TBPH	Theravance Biopharma Inc
12/02/2025	05:00	PR Newswire (US)	Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025	NASDAQ:TBPH	Theravance Biopharma Inc
21/01/2025	15:03	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:TBPH	Theravance Biopharma Inc
17/12/2024	05:00	PR Newswire (US)	Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference	NASDAQ:TBPH	Theravance Biopharma Inc
14/11/2024	08:53	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:TBPH	Theravance Biopharma Inc
14/11/2024	05:06	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:TBPH	Theravance Biopharma Inc
12/11/2024	15:05	PR Newswire (US)	Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value	NASDAQ:TBPH	Theravance Biopharma Inc
24/10/2024	05:00	PR Newswire (US)	Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024	NASDAQ:TBPH	Theravance Biopharma Inc
18/10/2024	08:00	PR Newswire (US)	Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease	NASDAQ:TBPH	Theravance Biopharma Inc
05/08/2024	15:05	PR Newswire (US)	Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update	NASDAQ:TBPH	Theravance Biopharma Inc
22/07/2024	05:00	PR Newswire (US)	Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024	NASDAQ:TBPH	Theravance Biopharma Inc
11/06/2024	15:17	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:TBPH	Theravance Biopharma Inc
13/05/2024	15:05	PR Newswire (US)	Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update	NASDAQ:TBPH	Theravance Biopharma Inc
29/04/2024	05:00	PR Newswire (US)	Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024	NASDAQ:TBPH	Theravance Biopharma Inc
10/04/2024	05:00	PR Newswire (US)	Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024	NASDAQ:TBPH	Theravance Biopharma Inc
26/02/2024	15:05	PR Newswire (US)	Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	NASDAQ:TBPH	Theravance Biopharma Inc
16/02/2024	19:12	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:TBPH	Theravance Biopharma Inc
14/02/2024	15:00	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:TBPH	Theravance Biopharma Inc
14/02/2024	05:00	PR Newswire (US)	Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024	NASDAQ:TBPH	Theravance Biopharma Inc
05/01/2024	05:00	PR Newswire (US)	Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)	NASDAQ:TBPH	Theravance Biopharma Inc
21/12/2023	16:10	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:TBPH	Theravance Biopharma Inc
21/12/2023	16:00	PR Newswire (US)	Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors	NASDAQ:TBPH	Theravance Biopharma Inc
18/12/2023	05:00	PR Newswire (US)	Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference	NASDAQ:TBPH	Theravance Biopharma Inc
16/11/2023	05:00	PR Newswire (US)	Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous System	NASDAQ:TBPH	Theravance Biopharma Inc
15/11/2023	05:00	PR Newswire (US)	Theravance Biopharma to Participate in the 6th Annual Evercore ISI HealthCONx Conference	NASDAQ:TBPH	Theravance Biopharma Inc
13/11/2023	07:00	PR Newswire (US)	Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)	NASDAQ:TBPH	Theravance Biopharma Inc